Similarly, dual expression of CD133 and EpCAM has been employed in hepatocellular and colorectal cancers to identify subpopulations with increased clonogenic potential and poor prognosis.54,198 In metastatic colorectal cancer, the coexpression of CD44v6 and LGR5 has emerged as a promising biomarker associated with enhanced metastatic behavior and drug resistance.140 These combinatorial marker systems provide a more nuanced understanding of CSC heterogeneity, enabling better stratification of patients, improved functional assays, and the development of more effective targeted therapies. Here, PROM1 is linked to colorectal cancer.